New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.

New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.

A low-mineral quark matrix is suggested, which is obtainable by (a) subjecting raw milk to heat treatment, separating the cream, (b) subjecting the skimmed milk such obtained to an ultrafiltration step and/or a reverse osmosis step, producing a retentate R1, which represents a dairy protein concentrate, and a permeate P1, (c) subjecting the permeate P1 to an electrodialysis step, producing a salt-depleted diluate D1, (d) combining the diluate D1 with the retentate R1, (e) subjecting the combination product such obtained to heat treatment until denaturation sets in, (f) fermenting the denaturation product such obtained by the addition of starter cultures and rennet, and (g) adjusting or standardising the fermentation product such obtained to defined dry matter and protein contents.

A quark matrix having improved taste characteristics is suggested, which is obtainable by (a) subjecting raw milk to heat treatment, separating the cream, (b) subjecting the skimmed milk such obtained to a microfiltration step, obtaining a first retentate R1, which represents a first dairy protein concentrate, and a first permeate P1, (c) subjecting the permeate P1 to an ultrafiltration step and/or a reverse osmosis step, obtaining a second retentate R2, which represents a second dairy protein concentrate, and a second permeate P2, (d) subjecting the permeate P2 to an electrodialysis step, obtaining a salt-depleted diluate D1, (e) combining the diluate D1 with the retentate R1, (f) subjecting the combination product such obtained to heat treatment until denaturation sets in, (g) fermenting the denaturation product such obtained by adding starter cultures and rennet, and (h) adjusting the fermentation product such obtained to defined dry matter and protein contents.

The present invention relates to fermentation processes. The objective of the invention was to provide methods for producing nisin containing ferments and formulating such ferments into preservatives. It was in particular an object of the present invention to provide improved processes for producing nisin containing ferments by simple and efficient (batch) culturing and allowing for simple down-stream processing either into a liquid, semi-liquid or a dry powder product, having sufficient nisin content and stability, good handling properties and satisfactory organoleptic properties. Such processes are provided, as well as the products that can be obtained with it and their use as food preservative.

The present invention relates to a novel strain having the activity of reducing advanced glycation end products and a use thereof and, more particularly, to a food composition having the activity of reducing advanced glycation end products and a pharmaceutical composition for preventing or treating a disease caused by advanced glycation end products each of which comprises a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, or a Lactobacillus paracasei KF00816 (accession number KCCM11998P) strain, which are all novel strains; a lysate thereof; or a culture thereof as an active ingredient. In addition, the present invention relates to a composition for intestinal regulation, a probiotic composition, a feed composition, and a fermented product, each of which comprises the novel strain of the present invention, a lysate thereof, or a culture thereof as an active ingredient.

The present invention relates to a novel strain having the activity of reducing advanced glycation end products and a use thereof and, more particularly, to a food composition having the activity of reducing advanced glycation end products and a pharmaceutical composition for preventing or treating a disease caused by advanced glycation end products each of which comprises a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, or a Lactobacillus paracasei KF00816 (accession number KCCM11998P) strain, which are all novel strains; a lysate thereof; or a culture thereof as an active ingredient. In addition, the present invention relates to a composition for intestinal regulation, a probiotic composition, a feed composition, and a fermented product, each of which comprises the novel strain of the present invention, a lysate thereof, or a culture thereof as an active ingredient.

The present invention relates to the field of microbiology, specifically the field of production of a dairy food product using fermentation and the field of gene transfer by conjugation.

The present invention relates to the field of microbiology, specifically the field of production of a dairy food product using fermentation and the field of gene transfer by conjugation.

The present invention provides a Lactococcus lactis subspecies lactis isolate WFLU-12 with the accession number of KCTC 13180BP, and a use thereof.